formation of nonracemic products.4 We anticipated LA-mediated
ring-opening of aziridines and azetidines to follow SN2 pathways
which would enable the design of enantioselective ring-opening
reactions of chiral aziridines and azetidines toward enantiopure
targets.
Lewis Acid-Mediated Highly Regioselective
SN2-Type Ring-Opening of
2-Aryl-N-tosylazetidines and Aziridines by
Alcohols
During our synthetic and mechanistic investigations on LA-
mediated ring-opening of azetidines, we have developed an
efficient strategy for nucleophilic ring-opening of 2-aryl-N-
sulfonylazetidines followed by (i) a novel rearrangement to
allylamines5a and (ii) [4 + 2] cycloaddition with carbonyl
compounds to nonracemic 1,3-oxazinanes.5b Our observations
provide convincing evidence that the rearrangement or the
cycloaddition proceeds through an SN2-type pathway, instead
of a 1,4-dipole as invoked earlier.2e-g We have also demon-
strated the ring-opening of chiral 2-phenyl-N-tosylaziridine
followed by cycloaddition with carbonyl compounds to give a
variety of nonracemic 1,3-oxazolidines Via an SN2-type pathway.5c
To rule out the SN1 pathway through the intermediacy of a stable
1,4-dipole, the nucleophilic ring-opening of 2-aryl-N-tosylaze-
tidines 1 in polar and protic alcohol (methyl, benzyl, propargyl,
etc.) medium was studied where the solvent served as the
nucleophile. We report, herein, an expedient approach for a
direct access to nonracemic 1,3-amino ethers with excellent
yields and high ee (up to 90%) by the regioselective nucleophilic
ring-opening of chiral 2-phenyl-N-tosylazetidine with alcohols.
Biologically active amino ethers of general structure 2 (Figure
1) are widely used for the treatment of anxiety and depression
and their analogues belong to a class of potent and selective
serotonin and norepinephrin reuptake inhibitors.6-9
Manas K. Ghorai,* Kalpataru Das, and Dipti Shukla
Department of Chemistry, Indian Institute of Technology,
Kanpur, 208016, India
ReceiVed March 6, 2007
Lewis acid-mediated highly regioselective SN2-type ring-
opening of 2-aryl-N-tosylazetidines with alcohols to afford
various 1,3-amino ethers in excellent yields with good
enantiomeric excess is described. Similar SN2-type ring-
opening of chiral 2-phenyl-N-tosylaziridine with various
alcohols produces the corresponding nonracemic 1,2-amino
ethers in excellent yields and good ee. The mechanism of
the ring-opening of aziridines and azetidines Via an SN2
pathway is supported by the formation of nonracemic amino
ethers.
Although few reports are available in the literature for the
synthesis of 1,3-amino ethers,10 there is no report for the
synthesis of these amino ethers Via LA-mediated nucleophilic
ring-opening of 2-aryl-N-tosylazetidines with alcohols. Chiral
1,2-amino ethers as essential fragments in many glycopeptide
antibiotics11 and ether-containing peptide bond surrogate units12
are important for several biological processes. Alkoxide- or
Aziridines and azetidines are valuable building blocks in
organic synthesis because of their ability to undergo ring-
opening,1 cycloaddition,2 and fragmentation3 reactions. We have
recently reported Lewis acid (LA)-mediated nucleophilic ring-
opening and cycloaddition of 2-aryl-N-tosylazetidines and
aziridines to provide nonracemic products, and a mechanism
was proposed Via an SN2-type pathway to rationalize the
(2) For cycloaddition of aziridines: (a) Concello´n, J. M.; Riego, E.;
Sua´rez, J. R.; Garc´ıa-Granda, S.; D´ıaz, M. R. Org. Lett. 2004, 6, 4499-
4501. (b) Zhu, W.; Cai, G.; Ma, D. Org. Lett. 2005, 7, 5545-5548. (c)
Ghorai, M. K.; Ghosh, K.; Das, K. Tetrahedron Lett. 2006, 47, 5399-
5403 and references cited therein. For cycloaddition of azetidines: (d)
Ungureanu, I.; Klotz, P.; Schoenfelder, A.; Mann, A. Chem. Commun. 2001,
958-959. (e) Ungureanu, I.; Klotz, P.; Schoenfelder, A.; Mann, A.
Tetrahedron Lett. 2001, 42, 6087-6091. (f) Prasad, B. A. B.; Bisai, A.;
Singh, V. K. Org. Lett. 2004, 6, 4829-4831. (g) Yadav, V. K.; Sriramurthy,
V. J. Am. Chem. Soc. 2005, 127, 16366-16367. (h) Baeg, J. O.; Bensimon,
C.; Alper, H. J. Org. Chem. 1995, 60, 253-256. (i) Baeg, J. O.; Bensimon,
C.; Alper, H. Ibid. 1995, 60, 3092-3095.
(3) Alcaide, B.; Almendros, P.; Aragoncillo, C.; Salgado, N. R. J. Org.
Chem. 1999, 64, 9596-9604 and the referrences cited therein.
(4) (a) Ghorai, M. K.; Das, K.; Kumar, A.; Ghosh, K. Tetrahedron Lett.
2005, 46, 4103-4106. (b) Ghorai, M. K.; Das, K.; Kumar, A.; Das, A.
Tetrahedron Lett. 2006, 47, 5393-5397. (c) Ghorai, M. K.; Ghosh, K.:
Das, K. Tetrahedron Lett. 2006, 47, 5399-5403.
(5) (a) Ghorai, M. K.; Kumar, A.; Das, K. Unpublished results. (b)
Ghorai, M. K.; Das, K.; Kumar, A. Tetrahedron Lett. 2007, doi: 10.1016/
j.tetlet.2007.04.097. (c) Ghorai, M. K.; Ghosh, K. Tetrahedron Lett. 2007,
48, 3191-3195.
(6) Robertson, D. W.; Jones, N. D.; Swartzendruber, J. K.; Yang, K. S.;
Wong, D. T. J. Med. Chem. 1988, 31, 185-189 and references cited therein.
(7) Silver, H. Int. Clin. Psychopharm. 2003, 18, 305-313.
(8) Wong, D. T.; Bymaster, F. P.; Engleman, E. A. Life Sci. 1995, 57,
411-441.
(9) Chouinard, G.; Annable, L.; Bradwejn, J. Psychopharmacology 1984,
83, 126-128.
* To whom correspondence should be addressed. Tel: +91-512-2597518;
Fax: +91-512-2597436.
(1) For ring opening of aziridines: (a) Hu, X. E. Tetrahedron 2004, 60,
2701-2743 and references cited therein. (b) Minakata, S.; Okada, Y.;
Oderaotoshi, Y.; Komatsu, M. Org. Lett. 2005, 7, 3509-3512. (c) Ding,
C. H.; Dai, L. X.; Hou, X. L. Tetrahedron 2005, 61, 9586-9593. (d)
Pineschi, M.; Bertolini, F.; Haak, R. M.; Crotti, P.; Macchia, F. Chem.
Commun. 2005, 1426-1428. (e) Minakata, S.; Hotta, T.; Oderaotoshi, Y.;
Komatsu, M. J. Org. Chem. 2006, 71, 7471-7472. (f) Fukuta, Y.; Mita,
T.; Fukuda, N.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2006, 128,
6312-6313. (g) De Kimpe, N. Three- and Four-Membered Rings, With
All Fused Systems Containing Three- and Four-Membered Rings. In
ComprehensiVe Heterocyclic Chemistry II; Padwa, A., Ed.; Elsevier: Oxford
1996; Vol. 1, Chapter 1.21. For ring opening of azetidines: (h) Almena,
J.; Foubelo, F.; Yus, M. Tetrahedron 1994, 50, 5775-5782. (i) Akiyama,
T.; Daidouji, K.; Fuchibe, K. Org. Lett. 2003, 5, 3691-3693. (j) Vargas-
Sanchez, M.; Couty, F.; Evano, G.; Prim, D.; Marrot, J. Org. Lett. 2005, 7,
5861-5864. (k) Domostoj, M.; Ungureanu, I.; Schoenfelder, A.; Klotz, P.;
Mann, A. Tetrahedron Lett. 2006, 47, 2205-2208. (l) Van Brabandt, W.;
Van Landeghem, R.; De Kimpe, N. Org. Lett. 2006, 8, 1105-1108. (m)
Golding, P; Millar, R. W.; Paul, N. C.; Richards, D. H. Tetrahedron 1995,
51, 5073-5082. (n) Vanecko, J. A.; West, F. G. Org. Lett. 2005, 7, 2949-
2952.
10.1021/jo0703294 CCC: $37.00 © 2007 American Chemical Society
Published on Web 06/26/2007
J. Org. Chem. 2007, 72, 5859-5862
5859